{Reference Type}: English Abstract
{Title}: [Central nervous system disorders on lorlatinib: How to detect and manage in practice?]
{Author}: Fallet V;Rouby P;Ahle G;Arrondeau J;Naltet C;Duflot-Boukobza A;De Crozals F;Lena H;Cortot A;Fallet V;Rouby P;Ahle G;Arrondeau J;Naltet C;Duflot-Boukobza A;De Crozals F;Lena H;Cortot A;
{Journal}: Bull Cancer
{Volume}: 109
{Issue}: 4
{Year}: Apr 2022
{Factor}: 1.318
{DOI}: 10.1016/j.bulcan.2022.01.011
{Abstract}: The therapeutic arsenal for advanced ALK positive non-small cell lung cancer has been enriched by specific treatments targeting this molecular abnormality, with five molecules available, including lorlatinib, approved since July 2020. This treatment can have side effects common to other tyrosine kinase inhibitors, as well as other less common disorders affecting the central nervous system such as impaired cognitive function, speech or mood. The prevalence of neuro-psychiatric effects under treatment with lorlatinib reported in studies is nearly 40 % with a mild to moderate intensity in most cases. Given the potential impact on patients' quality of life and even on compliance with treatment, it is essential to include their detection during consultations. The main problem is still to have simple screening tools adapted to clinical practice. A multidisciplinary expert panel (pulmonologist, medical oncologist, psychiatrist, neurologist, pharmacist, nurse) therefore met to propose, based on data from the literature and their clinical experience, elements of management in order to detect these cognitive disorders at an early stage and optimize treatment tolerance. The subjects discussed concern screening and assessment tools, the management of side effects, and their prevention. The use of the practical elements proposed by the group could help optimize the identification and management of central nervous system disorders occurring on lorlatinib.